Medical Oncology

Obesity Medicine

Questions discussed in this category

Should GLP-1 agonists be held during chemotherapy?

How do you counsel patients on semaglutide or tirzepatide in light of potential cancer risks?

Do you avoid using these agents only in patients with history of medullary thyroid cancer or pancreatic cancer? Are there other cancer risks we should...

1 Answer available

Papers discussed in this category

BMC endocrine disorders, 2024 Nov 18

Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.

International urology and nephrology, 2024 Nov 04

Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.

Cancers, 2024 Sep 22

Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis.

BMJ open, 2024 Oct 09

Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study.

JAMA network open, 2024 Jul 01

Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.

Medical Oncology

Obesity Medicine

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology